Alkermes Inc. plc (ALKS) Stock Price
ALKSStock
$41.22+33.83%52W
Market Cap$6.92B
P/E28.61x
PEG Ratio1.96
Div yield—
Beta0.25
ALKS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)11.80%
Price vs S&P 500 (4W)-5.37%
PEG Ratio1.96
VGM Score51.28
P/E Ratio (Annual)28.61x
ALKS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.29 | $0.70 | +141.33%(+$0.41) | |
| Q1 2026 | -$0.04 | $0.38 | +1053.00%(+$0.42) | |
| Q4 2025 | $0.45 | $0.48 | +7.74%(+$0.03) | |
| Q3 2025 | $0.39 | $0.65 | +68.54%(+$0.26) | |
| Q2 2025 | $0.40 | $0.68 | +71.14%(+$0.28) |
ALKS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.09
4.04
3.96
3.96
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ALKSAlkermes Inc. plc | D | C | B | 4.1x | 10.8% | 84.6% | — | $41.22 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Alkermes Inc. plc
Alkermes is a fully integrated biotechnology company specializing in pharmaceutical products for unmet medical needs through proprietary formulation technologies. The company develops products by partnering with third-party drug suppliers and licensees, providing integrated capabilities in research, development, manufacturing, and commercialization. Primary revenue comes from the U.S., with additional operations in Ireland and international markets.